Eplerenone Improves Pulmonary Vascular Remodeling and Hypertension by Inhibition of the Mineralocorticoid Receptor in Endothelial Cells

Hypertension. 2021 Aug;78(2):456-465. doi: 10.1161/HYPERTENSIONAHA.120.16196. Epub 2021 May 10.

Abstract

[Figure: see text].

Keywords: aldosterone; cardiovascular disease; endothelial cells; mineralocorticoid receptor; pulmonary hypertension.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antihypertensive Agents / pharmacology*
  • Antihypertensive Agents / therapeutic use
  • Disease Models, Animal
  • Endothelial Cells / drug effects*
  • Endothelial Cells / metabolism
  • Endothelium, Vascular / drug effects*
  • Endothelium, Vascular / metabolism
  • Eplerenone / pharmacology*
  • Eplerenone / therapeutic use
  • Hypertension, Pulmonary / drug therapy*
  • Hypertension, Pulmonary / metabolism
  • Male
  • Mice
  • Mice, Knockout
  • Mineralocorticoid Receptor Antagonists / pharmacology*
  • Mineralocorticoid Receptor Antagonists / therapeutic use
  • Receptors, Mineralocorticoid / genetics
  • Receptors, Mineralocorticoid / metabolism
  • Treatment Outcome
  • Vascular Remodeling / drug effects*

Substances

  • Antihypertensive Agents
  • Mineralocorticoid Receptor Antagonists
  • Receptors, Mineralocorticoid
  • Eplerenone